High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

• Status: Withdrawn
• Trial end date: 2022-12-01

Summary

The purpose of this study is to see if a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given with high dose Ascorbic Acid will be safe and effective in individuals with untreated metastatic pancreatic cancer.

Vitamin C is a nutrient found in food and dietary supplements. It protects cells and also plays a key role in making collagen (which provides strength and structure to skin, bones, tissues and tendons). High-dose vitamin C may be given by intravenous (IV) infusion (through a vein into the bloodstream) or orally (taken by mouth). When taken by intravenous infusion, vitamin C can reach much higher levels in the blood than when the same amount is taken by mouth. Some human studies of high-dose IV vitamin C in patients with cancer have shown improved quality of life, as well as improvements in physical, mental, and emotional functions, symptoms of fatigue, nausea and vomiting, pain, and appetite loss. Intravenous high-dose ascorbic acid has caused very few side effects in clinical trials.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Hitendra Patel
• Collaborators: Cancer Research UK; Destroy Pacreatic Cancer Foundation; Destroy Pancreatic Cancer; HonorHealth Research Institute; Lustgarten Foundation; Stand Up To Cancer; Translational Genomics Research Institute
• Treatments: Albumin-Bound Paclitaxel; Ascorbic Acid; Cisplatin; Gemcitabine; Paclitaxel; Vitamins